Skip to content

Study · Not a test of the peptide alone · 2007

4 results

Influence of the N terminus and the actin-binding motif of thymosin beta4 on its interaction with G-actin.

Zoubek RE, Hannappel E

Annals of the New York Academy of Sciences10 May 2007Cited by 3 (Europe PMC)

PMID17495251 (opens in a new tab)DOI10.1196/annals.1415.026 (opens in a new tab)PepBankPUB-17495251
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    The complex of G-actin with nonacetylated Tbeta4 or the A7V variant was more stable than the complex with naturally occurring, acetylated Tbeta4.

    In plain wordsIn lab tests, nonacetylated thymosin beta‑4 and the A7V variant bound actin more stably than the natural, acetylated form.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseG-actin complex stability of nonacetylated Tbeta4 and A7V variant
    Study

    n: not reported in source

    purified G-actin with E. coli-generated Tbeta4 variants
    Comparator
    Naturally occurring acetylated Tbeta4
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The stability of the complex of G-actin with nonacetylated thymosin beta(4) or beta(4)(A7V) is higher than the one with naturally occurring thymosin beta(4), which is always acetylated.
    1 context sentence
    Summary · context
    We generated thymosin beta(4) variants with amino acid substitutions within the N-terminal alpha-helix and the putative actin-binding motif.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    The G-actin complexes of nonacetylated Tbeta4(A7V,K18,19A) and Tbeta4(K14,16,18,19A) were 15 times less stable than the complex with Tbeta4.

    In plain wordsIn lab tests, two changed versions of thymosin beta‑4 formed actin complexes that were 15 times less stable than the original.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseG-actin complex stability of multi-substitution variants
    Study

    n: not reported in source

    purified G-actin with E. coli-generated Tbeta4 variants
    Comparator
    Tbeta4
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    relative complex stability
    15 times less stable
    A7V,K18,19A and K14,16,18,19A variants

    Source sentences

    Summary
    The complex of G-actin with nonacetylated thymosin beta(4)(A7V,K18,19A) and beta(4)(K14,16,18,19A) is 15 times less stable compared to the complex with thymosin beta(4).
    1 context sentence
    Summary · context
    We generated thymosin beta(4) variants with amino acid substitutions within the N-terminal alpha-helix and the putative actin-binding motif.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    G-actin sequestering activities of the Tbeta4 variants corresponded to their complex stabilities, except for nonacetylated Tbeta4(A7V), where it was attenuated.

    In plain wordsIn lab tests, the actin-holding activity of thymosin beta‑4 variants matched their binding stability, except one variant where it was weaker.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    MixedG-actin sequestering activity of Tbeta4 variants
    Study

    n: not reported in source

    purified G-actin with E. coli-generated Tbeta4 variants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The G-actin sequestering activities of all thymosin beta(4) variants correspond to their complex stabilities with G-actin, except for nonacetylated thymosin beta(4)(A7V), where it is attenuated.
    1 context sentence
    Summary · context
    We generated thymosin beta(4) variants with amino acid substitutions within the N-terminal alpha-helix and the putative actin-binding motif.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    Tbeta4(Delta17-23), missing the putative actin-binding motif, showed no interaction with G-actin.

    In plain wordsIn lab tests, a thymosin beta‑4 version missing the actin-binding motif did not interact with actin.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeG-actin interaction of Tbeta4(Delta17-23)
    Study

    n: not reported in source

    purified G-actin with E. coli-generated Tbeta4 variants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Thymosin beta(4)(Delta17-23) missing the putative actin-binding motif shows no interaction with G-actin.
    1 context sentence
    Summary · context
    We generated thymosin beta(4) variants with amino acid substitutions within the N-terminal alpha-helix and the putative actin-binding motif.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.